Asston Pharmaceuticals
79.94
0.00(0.00%)
Market Cap₹68.10 Cr
PE Ratio-
Company Performance:
1D0.00%
1M-8.42%
6M+2.90%
1Y-36.02%
5Y-36.02%
View Company Insightsright
More news about Asston Pharmaceuticals
21Jan 26
Asston Pharmaceuticals Commences Commercial Production at Unit II Facility in Maharashtra
Asston Pharmaceuticals Limited commenced commercial production at its Unit II facility on January 21, 2026, located in MIDC Ambernath, Maharashtra. The new manufacturing unit will produce pharmaceuticals and nutraceuticals products as per the company's scheduled expansion plan. This development follows their November 2025 communication regarding capacity addition and represents a significant operational milestone for the BSE-listed pharmaceutical company.
 no imag found
05Jan 26
Asston Pharmaceuticals Board Approves ₹1 Crore Car Loan Facility from HDFC Bank
Asston Pharmaceuticals Limited's board approved a car loan facility worth up to ₹1.00 crore from HDFC Bank Limited on January 5, 2026. The loan will be secured against the vehicles purchased with the proceeds, with specific terms to be finalized in the formal agreement. The company has complied with SEBI disclosure requirements by informing BSE Limited of this material development.
 no imag found
16Oct 25
Asston Pharmaceuticals Bolsters Leadership and Secures Funding for Expansion
Asston Pharmaceuticals has made key appointments and secured funding to support growth. The board appointed Yogesh Supekar as Additional Non-Executive Non-Independent Director, Rishi Upadhaya as Company Secretary and Compliance Officer, and M/s Yash A. Jain & Associates as internal auditor. The company approved an interest-free unsecured loan of up to Rs 3.00 crore from directors and a secured loan of up to Rs 2.70 crore from HDFC Bank for purchasing commercial space.
 no imag found
13Oct 25
Key Personnel Changes at Asston Pharmaceuticals: CFO and Company Secretary Resign
Asston Pharmaceuticals Limited announced the resignation of two key personnel. Deven Manohar Patil, the Chief Financial Officer, and Vandana Mishra, the Company Secretary and Compliance Officer, have both stepped down from their positions effective October 13, 2025. Both cited the pursuit of new career opportunities outside the company as their reason for leaving. The company's Whole Time Director, Saili Jayaram More, filed regulatory disclosures in compliance with SEBI regulations to inform stakeholders of these changes.
 no imag found
31Jul 25
Asston Pharmaceuticals Secures USD 279,000 International Order from West African Pharma Company
Asston Pharmaceuticals Limited has received a purchase order worth USD 279,000 from a West African pharmaceutical company for various pharmaceutical products. The order is to be executed within 60 days and is not a related party transaction. This international order demonstrates Asston's growing global presence and operational efficiency in the pharmaceutical market.
 no imag found
1 Year Returns:-36.02%
Industry Peers
Waaree Energies
3,230.10
(+0.11%)
Apar Industries
12,810.00
(+0.07%)
Premier Energies
1,011.60
(-0.68%)
Avalon Technologies
1,387.00
(+10.47%)
Vikram Solar
214.74
(-4.67%)
Saatvik Green Energy
471.15
(-1.43%)
Shilchar Technologies
4,315.00
(-1.70%)
Websol Energy System
114.94
(+0.10%)